Headlines about Corium International (NASDAQ:CORI) have trended somewhat positive on Sunday, Accern Sentiment reports. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Corium International earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 44.7858301877092 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Here are some of the news stories that may have effected Accern Sentiment Analysis’s rankings:

A number of equities research analysts have commented on CORI shares. Needham & Company LLC reissued a “buy” rating and set a $13.00 price objective on shares of Corium International in a report on Sunday, September 17th. WBB Securities raised shares of Corium International to a “buy” rating and set a $13.00 price objective on the stock in a report on Friday, July 7th. Zacks Investment Research raised shares of Corium International from a “hold” rating to a “buy” rating and set a $8.50 price objective on the stock in a report on Tuesday, June 6th. BidaskClub lowered shares of Corium International from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 25th. Finally, Jefferies Group LLC reissued a “buy” rating and set a $8.00 price objective on shares of Corium International in a report on Wednesday, July 19th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Corium International currently has a consensus rating of “Buy” and an average price target of $12.56.

Shares of Corium International (CORI) opened at 11.08 on Friday. The firm’s market capitalization is $396.02 million. Corium International has a 12 month low of $2.67 and a 12 month high of $11.28. The company has a 50 day moving average of $8.44 and a 200-day moving average of $6.67.

Corium International (NASDAQ:CORI) last announced its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.43) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.13). Corium International had a negative net margin of 145.60% and a negative return on equity of 673.17%. The company had revenue of $8.11 million during the quarter, compared to the consensus estimate of $8.71 million. Analysts predict that Corium International will post ($1.70) EPS for the current year.

In related news, insider Parminder Singh sold 32,000 shares of the company’s stock in a transaction that occurred on Thursday, August 17th. The stock was sold at an average price of $7.61, for a total value of $243,520.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CAO Timothy D. Sweemer sold 12,012 shares of the company’s stock in a transaction that occurred on Thursday, August 17th. The shares were sold at an average price of $7.62, for a total value of $91,531.44. The disclosure for this sale can be found here. Insiders sold 91,953 shares of company stock worth $705,258 over the last quarter. 46.50% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY WARNING: This article was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another website, it was illegally stolen and reposted in violation of international trademark & copyright laws. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/10/01/corium-international-cori-receives-daily-news-impact-score-of-0-10.html.

About Corium International

Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.

Insider Buying and Selling by Quarter for Corium International (NASDAQ:CORI)

Receive News & Stock Ratings for Corium International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International Inc. and related stocks with our FREE daily email newsletter.